Zilebesiran in Combination with a Standard-of-care . . . - Alnylam The Phase 2 KARDIA-3 study (NCT06272487) has been initiated and will evaluate patients with hypertension uncontrolled by 2-4 standard-of-care antihypertensives who have high cardiovascular risk or advanced chronic kidney disease
KARDIA: Zilebesiran Phase 2 Clinical Development Overview KARDIA-3 is a Phase 2 randomized, DB, placebo-controlled, two-cohort study to evaluate the eficacy and safety of zilebesiran in combination with two to four antihypertensive medications in adult patients with uncontrolled hypertension at high CV risk 6
Roche and Alnylam report positive topline results from the Phase II . . . Basel, 05 March 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase II KARDIA-2 study [NCT05103332] of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension (high blood pressure) - the leading cause of cardiovascular disease worldwide 1 - met its primary endpoint
KARDIA-2: Novel BP-Lowering Drug Reduces SBP With Just One Injection The phase 2, double-blind, placebo-controlled study, presented by Akshay S Desai, MD, FACC, evaluated the efficacy and safety of adding zilebesiran, which blocks production of angiotensinogen, in 672 patients (59 years old, 43% women, 28% Black)
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of . . . The KARDIA-2 Phase 2 study is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of zilebesiran, when added to standard of care antihypertensive medications, in adults with mild-to-moderate hypertension
Detailed Results from the KARDIA-2 Phase 2 study of Zilebesiran . . . Detailed results from the KARDIA-2 Phase 2 study supporting the safety and efficacy of zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension, when used in combination with one of three standard classes of antihypertensive medications were published in The Journal of the American Medical Association
Календарь